Immunogenic Oxidized Low-density Lipoprotein/β2-glycoprotein I Complexes in the Diagnostic Management of Atherosclerosis

被引:23
作者
Lopez, Luis R. [1 ]
Kobayashi, Kazuko [2 ]
Matsunami, Yukana [2 ]
Matsuura, Eiji [2 ]
机构
[1] Corgenix Inc, Broomfield, CO 80020 USA
[2] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Cell Chem, Okayama 7008558, Japan
关键词
Atherosclerosis; Autoimmunity; Antiphospholipid antibodies; beta; 2GPI; Oxidized LDL; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTIPHOSPHOLIPID ANTIBODIES; ANTICARDIOLIPIN ANTIBODIES; BETA(2)-GLYCOPROTEIN I; RISK-FACTORS; ACCELERATED ATHEROSCLEROSIS; DEPENDENT UPTAKE; ISCHEMIC-STROKE; LIPOPROTEIN; THROMBOSIS;
D O I
10.1007/s12016-008-8096-8
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Oxidized low-density lipoprotein (oxLDL) promotes atherosclerosis through a complex interaction of inflammatory and immunologic factors that lead to macrophage lipid uptake and foam cell formation. OxLDL interacts with beta 2-glycoprotein I (beta 2GPI) forming oxLDL/beta 2GPI complexes. These complexes may be formed in the arterial intima during atherogenesis and released into the circulation. Autoantibodies against oxLDL/beta 2GPI complexes have been demonstrated in patients with systemic lupus erythematosus and/or antiphospholipid syndrome, and shown to be significantly associated with arterial thrombosis. The observation that monoclonal autoantibodies against oxLDL/beta 2GPI complexes significantly increased the oxLDL uptake by macrophages strongly suggests that such IgG autoantibodies are pro-atherogenic. In this article, we review the recent progress in our understanding of LDL oxidation, oxLDL/beta 2GPI complex formation, and immune regulation of atherogenesis.
引用
收藏
页码:12 / 19
页数:8
相关论文
共 70 条
  • [51] Ongoing prothrombotic state in patients with antiphospholipid antibodies:: A role for increased lipid peroxidation
    Praticò, D
    Ferro, D
    Iuliano, L
    Rokach, J
    Conti, F
    Valesini, G
    FitzGerald, GA
    Violi, F
    [J]. BLOOD, 1999, 93 (10) : 3401 - 3407
  • [52] Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus
    Roman, MJ
    Shanker, B
    Davis, A
    Lockshin, MD
    Sammaritano, L
    Simantov, R
    Crow, MK
    Schwartz, JE
    Paget, SA
    Devereux, RB
    Salmon, JE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (25) : 2399 - 2406
  • [53] Autoimmunity: busting the atherosclerotic plaque
    Rose, N
    Afanasyeva, M
    [J]. NATURE MEDICINE, 2003, 9 (06) : 641 - 642
  • [54] Mechanisms of disease - Atherosclerosis - An inflammatory disease
    Ross, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (02) : 115 - 126
  • [55] ROUBEY RAS, 1994, BLOOD, V84, P2854
  • [56] AUTOANTIBODY AGAINST OXIDIZED LDL AND PROGRESSION OF CAROTID ATHEROSCLEROSIS
    SALONEN, JT
    YLAHERTTUALA, S
    YAMAMOTO, R
    BUTLER, S
    KORPELA, H
    SALONEN, R
    NYYSSONEN, K
    PALINSKI, W
    WITZTUM, JL
    [J]. LANCET, 1992, 339 (8798) : 883 - 887
  • [57] The cardiovascular burden of lupus - A complex challenge
    Schattner, A
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (13) : 1507 - 1510
  • [58] Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients
    Shah, NM
    Khamashta, MA
    Atsumi, T
    Hughes, GRV
    [J]. LUPUS, 1998, 7 (01) : 3 - 6
  • [59] β2-glycoprotein I:: Target antigen for 'antiphospholipid' antibodies.: Immunological and molecular aspects
    Sheng, Y
    Kandiah, DA
    Krilis, SA
    [J]. LUPUS, 1998, 7 : S5 - S9
  • [60] Low density lipoprotein oxidation and its pathobiological significance
    Steinberg, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (34) : 20963 - 20966